Publications
Learn about the research supporting our preclinical and clinical development programs

Publications

Learn about the research supporting our preclinical and clinical development programs

Presentations

13 November 2018
EORTC

Preliminary pharmacokinetic assessment of BT1718: Aphase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) in patients with advanced solid tumours

13 November 2018
EORTC

Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of cancer

12 November 2018
PEGS

Novel Multimers of Bicyclic Peptides Cluster and Activate CD137 (4-1BB): A Costimulatory T -Cell Checkpoint Receptor

6 November 2018
SITC

Novel Multimers of Bicyclic Peptides Cluster and Activate CD137 (4-1BB): A Costimulatory T-Cell Checkpoint Receptor

9 October 2018
ELRIG Drug Discovery

Novel Bicyclic Peptide Multimers Activate T Cell Costimulatory Protein CD137

9 October 2018
ELRIG Drug Discovery

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

1 October 2018
NCRI

A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours

31 August 2018
35th European Peptide Symposium

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

18 July 2018
Promega Biologics

Novel Bicycle Peptide Multimers Activate T Cell Costimulatory Protein CD137

5 June 2018
ASCO

A Cancer Research UK phase I/IIatrial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours

14 April 2018
AACR

Bicycle Toxin Conjugates (BTCs) targeting EphA2 for the treatment of solid tumours: Discovery and selection of BT5528

14 April 2018
AACR

BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2 has potent anti-tumour activity without bleeding or coagulation abnormalities in animal models

14 April 2018
AACR

Small Synthetic, Multivalent Bicyclic Peptides That Activate T Cell Costimulatory Protein CD137

30 April 2017
PEGS

Bicyclic Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing tumours

30 April 2017
PEGS

The Bicycle platform: an efficient technology to generate high affinity, high selectivity molecules (Bicycles®) with unique drug like properties that are amenable to conjugation

30 April 2017
PEGS

Discovery and development of BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumours: In vitro and in vivo activities

30 April 2017
PEGS

BT1718, a novel Bicycle Drug Conjugate® shows potent anti-tumor activity in diverse cell-derived and patient-derived tumor xenograft models

30 April 2017
PEGS

Identification of high affinity, highly selective bicyclic peptides (Bicycles®) to transmembrane proteins using phage display screening on whole cells

1 April 2017
AACR

BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumours: Design of bicyclic peptide and linker selection

1 April 2017
AACR

Bicycle Peptides for Positron Emission Tomography (PET) Imaging of MT1-MMP Expressing Tumors

1 April 2017
AACR

Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer